Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ichiro Umeda to Take Helm of Pfizer Japan
December 14, 2009
- Large Gap between Korosho's Proposals and MOF's Requirements
December 14, 2009
- Takeda Aims at Entering South American Generics Market
December 14, 2009
- Ordinary NHI Price Cut Rate in FY2010 Expected to Be 6.4%
December 14, 2009
- Otsuka Extends Research Collaboration with Galenea for 1 More Year
December 14, 2009
- Medical Fees Should Be Increased: Mr Sengoku
December 14, 2009
- Hisamitsu to Enhance Operation Efficiency in US
December 14, 2009
- NHI Price Listing OK'd for 23 Products, 12 APIs
December 14, 2009
- Sanofi-aventis to Maintain Same Volume of Sales in 2010: Dr Chocat
December 14, 2009
- GSK Files for Rotavirus Vaccine Rotarix
December 14, 2009
- DSP to Spin Off Animal Health, Food & Speciality Products
December 14, 2009
- FDA Advisory Committee Supports Safety, Efficacy of Prevnar 13
December 14, 2009
- EFPIA Japan Appoints Masuhiro Kato Chairman
December 14, 2009
- More Than 60% of Patients Dissatisfied with Existing Oral Hypoglycemic Agents
December 14, 2009
- No New Safety Measures Required for Lantus: PMDA
December 14, 2009
- GRU's WG Demands Reductions in METI's Budgets for Drug Discovery Research
December 14, 2009
- Korosho Decides How to Respond to GRU's Recommendations
December 14, 2009
- 2-Year Extension OK'd for R&D Tax Breaks for Both Increased and High-Level Investment
December 14, 2009
- Merck Serono Aims to Launch Cancer Vaccine by 2015
December 14, 2009
- Takara Bio Begins PI Trial for Gene Therapy for Relapsed Leukemia
December 14, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…